What 'Ozempic babies' actually means
'Ozempic babies' is the nickname the media gave to a wave of unexpected pregnancies reported by people taking GLP-1 medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). It is not an official medical term, and these drugs are not fertility treatments. Still, the pattern is real enough that fertility specialists now routinely counsel patients about it (UT Southwestern, 2024).
There are two separate reasons a surprise pregnancy can happen on a GLP-1: the weight loss itself can restart ovulation, and — with tirzepatide specifically — the medication can make the birth-control pill less reliable. Understanding both is the key to planning ahead.
How GLP-1 weight loss can restore ovulation
Excess body weight can disrupt the hormones that drive ovulation. Losing roughly 5-10% of body weight can help some people who were not ovulating regularly return to normal cycles, which restores the ability to conceive (University Hospitals, 2025). In the SELECT trial, about 44% of participants on semaglutide lost more than 10% of their body weight within two years — enough, for many, to change fertility (UT Southwestern, 2024).
The effect is strongest in people with obesity or polycystic ovary syndrome (PCOS). GLP-1s can lower insulin resistance and reduce circulating testosterone, which helps regulate cycles in PCOS. Importantly, the drugs do not act directly on the ovaries or 'boost fertility' — they create the metabolic conditions in which ovulation can resume.
- Weight loss lowers excess estrogen produced by fat tissue and can normalize menstrual cycles.
- Lower insulin resistance and testosterone can restore ovulation in PCOS.
- Any fertility effect is a downstream result of weight loss, not a direct drug action.
The birth-control catch (the other reason for surprise pregnancies)
The second driver is a drug interaction with the oral contraceptive pill. The FDA label for tirzepatide (Mounjaro, Zepbound) advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method — such as condoms — for 4 weeks after starting the medication and for 4 weeks after each dose increase (Mounjaro Prescribing Information, 2025).
The reason is delayed gastric emptying: GLP-1s slow how fast the stomach empties, which can reduce how much of an oral medication is absorbed. That delay is largest after the first dose and after each dose increase, then fades over time. Contraceptives that are not swallowed — IUDs, implants, the shot, the patch, and the vaginal ring — are not affected.
This specific barrier-method warning is on the tirzepatide label, not the injectable semaglutide label: a drug-interaction study found semaglutide did not meaningfully change exposure to the pill's hormones (Wegovy Prescribing Information, 2025). Even so, if you rely on the pill and start any GLP-1, it is worth confirming your contraception plan with your clinician.
- Tirzepatide (Mounjaro/Zepbound) label: add a barrier or non-oral method for 4 weeks after starting and after each dose increase.
- Cause: delayed gastric emptying can reduce absorption of the pill, worst right after starting or increasing the dose.
- Non-oral methods (IUD, implant, shot, patch, ring) are unaffected.
- Injectable semaglutide did not significantly reduce pill hormone exposure in the label's study.
GLP-1s are not fertility drugs — and are stopped before pregnancy
No GLP-1 medication is approved to treat infertility or for use during pregnancy. The labels advise against use in pregnancy: weight loss offers no benefit to a pregnant patient, and animal reproduction studies have flagged potential fetal harm — including birth defects and reduced offspring growth at high doses (Wegovy Prescribing Information, 2025; MotherToBaby, 2023 and 2024). Human pregnancy data remain limited.
Because semaglutide has a long half-life, the Wegovy label tells people of reproductive potential to stop it at least 2 months before a planned pregnancy (Wegovy Prescribing Information, 2025). MotherToBaby explains it can take about six weeks for most semaglutide to clear the body, and about 30 days for tirzepatide (MotherToBaby, 2023 and 2024). Those washout windows are why 'stop well before you start trying' is the standard message.
- Not approved for fertility or pregnancy; labels advise against use in pregnancy.
- Semaglutide (Wegovy): stop at least 2 months before a planned pregnancy.
- Tirzepatide: about 30 days for most of the drug to clear (MotherToBaby).
- The concern rests on the long half-life plus animal reproductive-harm data — human data are limited.
Timing, washout, and talking to your clinician
How and when to stop is a decision for you and your clinician, not something to do abruptly on your own. If pregnancy is possible, preconception counseling should be part of starting a GLP-1, and it should cover contraception, a washout timeline, and how to manage weight and blood sugar after stopping (University Hospitals, 2025).
If you are actively trying to conceive, the general guidance is to have already stopped the medication and cleared the washout window first. If pregnancy is a someday-goal, make sure your contraception is reliable in the meantime — especially during the first month on tirzepatide and after each dose increase.
Men, compounded versions, and what is still unknown
Most of the fertility conversation focuses on women, but researchers are also studying men. Early findings suggest weight loss on GLP-1s may be associated with improved sperm measures, but the data are limited and preliminary — this is not a reason to use these drugs for fertility. As with women, any benefit appears tied to weight loss rather than a direct drug effect.
Compounded semaglutide and tirzepatide — versions made by compounding pharmacies rather than the brand manufacturer — are not FDA-approved and are not reviewed for the same quality and safety, even though they contain the same active ingredients. The same pregnancy precautions, contraception cautions, and washout timing should be assumed to apply; the safest course is to follow the brand-label guidance and ask your clinician.